Our Approach
IDRx is a clinical-stage biopharmaceutical company dedicated to developing and commercializing precision therapeutics for the treatment of cancers with well-characterized biology and significant unmet medical need. IDRx aims to address the limitations of today’s precision cancer medicines with highly potent and selective targeted therapies to stop key tumor escape mechanisms and prolong patients’ response to therapy. Founded in 2021, the IDRx team has deep expertise in drug development and have collectively contributed to the discovery, development, and commercialization of more than 10 approved products.
Our lead program: IDRX-42
IDRX-42 is an oral, small molecule KIT tyrosine kinase inhibitor (TKI) in clinical development as a monotherapy for the treatment of gastrointestinal stromal tumors (GIST). GIST is the most common subtype of soft tissue sarcoma occurring in the gastrointestinal tract, in which approximately 80% of all cases are driven by mutations in the KIT gene. IDRX-42 is designed to selectively target the most prevalent forms of KIT mutations that either drive the initial growth, proliferation, and survival of tumor cells, or confer resistance to currently available therapies.
IDRX-42 has the potential to improve outcomes for patients with GIST as a first- or second-line therapy, where the standards of care have remained unchanged for almost 20 years and significant unmet need remains.
We are evaluating IDRX-42 for the treatment of advanced GIST in our ongoing open-label Phase 1/1b clinical trial (StrateGIST 1) and anticipate initiating StrateGIST 3, a global, randomized, open-label Phase 3 registrational trial, to evaluate IDRX-42 as a second-line therapy in patients with GIST.
Our Team
Our team has deep expertise in drug development, and have collectively contributed to the discovery, development, and commercialization of more than 10 approved products.
Partners
Investors
